Bionomics Limited (NASDAQ:BNOX – Get Rating) – Equities research analysts at Cantor Fitzgerald dropped their FY2023 EPS estimates for Bionomics in a report issued on Thursday, September 15th. Cantor Fitzgerald analyst C. Duncan now expects that the company will earn ($3.26) per share for the year, down from their prior forecast of ($2.94). The consensus estimate for Bionomics’ current full-year earnings is ($2.49) per share.
Bionomics Stock Down 2.6 %
NASDAQ BNOX opened at $7.19 on Monday. The company has a fifty day simple moving average of $7.46 and a two-hundred day simple moving average of $7.81. Bionomics has a 12-month low of $5.70 and a 12-month high of $22.00.
Institutional Trading of Bionomics
Bionomics Company Profile
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.
- Get a free copy of the StockNews.com research report on Bionomics (BNOX)
- Kroger’s is Your One-Stop Consumer Staples Stock
- Adobe Perfects the Art of the Faceplant for Investors
- Tax Credits are the Incentives in the Inflation Reduction Act
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
Receive News & Ratings for Bionomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionomics and related companies with MarketBeat.com's FREE daily email newsletter.